Professional Documents
Culture Documents
Many traditional pharmacopeias include Aristolochia and related plants, which contain nephrotoxins and mutagens
in the form of aristolochic acids and similar compounds (collectively, AA). AA is implicated in multiple cancer types,
sometimes with very high mutational burdens, especially in upper tract urothelial cancers (UTUCs). AA-associated
kidney failure and UTUCs are prevalent in Taiwan, but AA’s role in hepatocellular carcinomas (HCCs) there remains
unexplored. Therefore, we sequenced the whole exomes of 98 HCCs from two hospitals in Taiwan and found that
78% showed the distinctive mutational signature of AA exposure, accounting for most of the nonsilent mutations in
INTRODUCTION Aristolochia and Asarum, as well as related plants (6, 7). Many of these
Mutational signature analysis provides a molecular epidemiological tool plants are used as herbal medicines (9–18). AA mutagenesis is thought
for detecting environmental exposures that cause cancers (1–5). This to stem from the formation of bulky adducts on purines (19–21). For
has important implications for public health by providing evidence to reasons that are imperfectly understood, but possibly related to better
substantiate causal links between exposures and tumors, providing repair of AA-guanine adducts, more accurate translesion synthesis
opportunities for primary and secondary prevention. Mutational sig- across AA-guanine adducts, or both, AA induces adenine-to-thymine
nature analysis may also affect clinical oncology in situations where (A>T) mutations almost exclusively (9, 20, 22–24).
identifiable mutagenic exposures suggest specific cancer risks or pre- In the early 1990s, inadvertent treatment with AA-containing herbs
ferred treatments. at a Belgian weight loss clinic caused kidney failure in ~100 women (25),
Mutational signature analysis has been particularly helpful in many of whom later developed bladder and upper tract urothelial
illuminating the epidemiology of tumors associated with aristolochic carcinomas (UTUCs) (9). Subsequently, additional reports of kidney
acids and their derivatives (collectively, AA). Among these com- failure and urothelial cancers due to AA poisoning appeared, and it
pounds, the in vitro toxicity and mutagenicity of aristolochic acids emerged that AA was also responsible for Balkan endemic nephropathy
and aristolactams have been most intensively studied (6–8). AAs in- (9). Taiwan also emerged as a hot spot for AA exposure based on pre-
clude potent mutagens and nephrotoxins present in plants in the genera scription records and high rates of kidney failure and UTUCs, which are
1
likely to be partly due to AA exposure (26–30). More recently, muta-
Centre for Computational Biology, Duke-NUS Medical School, Singapore 169857,
Singapore. 2Programme in Cancer and Stem Cell Biology, Duke-NUS Medical School, tional signature analysis and other lines of evidence have suggested that
Singapore 169857, Singapore. 3NUS Graduate School for Integrative Sciences and AA mutagenesis may be widespread in terms of both geography and
Engineering, Singapore 117456, Singapore. 4Laboratory of Cancer Epigenome, Division types of cancer affected (10). In particular, after we and others described
of Medical Science, National Cancer Centre Singapore, Singapore 169610, Singapore.
5
Lymphoma Genomic Translational Research Laboratory, Division of Medical Oncology,
a distinctive mutational signature of AA exposure in the genomes of
National Cancer Centre Singapore, Singapore 169610, Singapore. 6Cancer Science UTUCs from Taiwan (29, 30), this signature was also found in bladder
Institute of Singapore, National University of Singapore, Singapore 117599, Singapore.
7
carcinomas (BCs) from Taiwan and other regions (31), renal cell car-
SingHealth/Duke-NUS Precision Medicine Institute, Singapore 169609, Singapore. cinomas (RCCs) from Taiwan and the Balkans (32–34), intrahepatic bile
8
Genome Institute of Singapore, Singapore 138672, Singapore. 9Division of Urooncology,
Department of Urology, Chang Gung University and Memorial Hospital, Linkou, duct carcinomas from China (35), bile duct carcinomas from Singapore
Taoyuan 33305, Taiwan. 10Department of Gastroenterology and Hepatology, Chang (36), and hepatocellular carcinomas (HCCs) from China, Vietnam, and
Gung Memorial Hospital, Linkou, Taoyuan 33305, Taiwan. 11Department of General other Southeast Asian countries (29, 37–39).
Surgery, Chang Gung Memorial Hospital, Linkou, Taoyuan 33305, Taiwan. 12Department
of Surgery, National Taiwan University, Taipei 10051, Taiwan. 13Johns Hopkins Singapore,
Inference of high rates of AA exposure in Taiwan is based on the
Singapore 308433, Singapore. 14Institute of Molecular and Cell Biology, Singapore following evidence: (i) prescription records indicating about one-third
138673, Singapore. of the population exposed to AA (28), (ii) high rates of UTUCs and
*These authors contributed equally to this work. co-association of kidney failure and UTUCs (40, 41), (iii) presence of
†Corresponding author. Email: siming.shia@msa.hinet.net (S.-Y.H.); alexchang@
imc.jhmi.edu (A.Y.C.); teh.bin.tean@singhealth.com.sg (B.T.T.); steve.rozen@duke-nus. AA-DNA adducts associated with UTUCs and RCCs (26, 34), and
edu.sg (S.G.R.) (iv) presence of the AA mutational signature in UTUCs, BCs, and
RCCs from Taiwan (29–31, 34). However, despite the high amount of observed mutation spectra are better explained with a contribution from
AA exposure in Taiwan and reports of the AA mutational signature in the AA mutational signature [Catalogue of Somatic Mutations in
HCCs from China and other areas, AA exposure in Taiwan HCCs re- Cancer (COSMIC) signature 22] than without. We developed mSigAct
mains unexplored. because, to our knowledge, current approaches, most of which are based
on nonnegative matrix factorization (NMF), do not support statistical
inference of the presence or absence of a signature (3, 4, 50, 51). Briefly,
RESULTS the mSigAct test starts by generating optimal coefficients for recon-
Overview of somatic changes in 98 HCCs from Taiwan struction of the observed spectrum using the mutational signatures
To investigate the possible presence of the AA mutational signature in previously detected in HCCs. The test first does this without the AA
HCCs from Taiwan, we sequenced the exomes of 98 HCCs and signature (null hypothesis) and then with the AA signature (al-
matched nonmalignant tissues from two hospitals (table S1). Tumor ternative hypothesis). The test then carries out a standard likelihood
tissue was obtained from nonconsecutive patients, and inclusion in this ratio test on these two hypotheses. Supplementary Materials and
study was solely based on the availability of adequate DNA. Tumors Methods and codes S1 and S2 provide details on the test, its evaluation
were not selected based on suspicion of AA exposure. on synthetic data, and the code. mSigAct revealed strong evidence of
We sequenced whole exomes, with a mean of 95% targeted tumor AA exposure in 76 of the 98 HCCs (78% with FDR < 0.05; Fig. 2, Table 1,
bases with ≥30× coverage (table S2). We detected a total of 26,805 and table S9). Among tumors with the AA signature, there was a
somatic single-base substitution (SBS) mutations across the HCCs median of 2.26 AA signature mutations/Mb (mean, 4.94 AA signature
CTG>CAG
Mut count
(CAG>CTG)
59 19 129 111
0.00 0
T on transcribed strand
A>T on nontranscribed strand
B Taiwan AA bladder (130T)
0.15 800
168 76 28
0.0 0
16
18 8
0.0 0
0.00 0
Preceded by 5' A C G T A C G T A C G T A C G T A C G T A C G T
AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC AC
Followed by 3' GT GT GT GT GT GT GT GT GT GT GT GT GT GT GT GT GT GT GT GT GT GT GT GT
F 0.1
8 and 2
Taiwan
Hidden
AA HCC
}
Non-AA HCC
0.0
AA bladder
PC2
AA UTUC
AA cell line
Others
China
Japan
0.0
PC1
Fig. 1. Evidence of AA exposure in Taiwan HCCs. (A and B) Sample exome spectra of individual AA-exposed UTUCs (A) and BCs (B) from Taiwan. (C and D) Sample exome
spectra of individual Taiwan HCCs with high (C) and moderate (D) levels of the AA signature. (E) Sample Taiwan HCC without AA signature. In the major plots in (A) to (E),
each bar indicates the proportion of mutations in a particular trinucleotide context. In the AA signature (A to D), the overwhelming majority of mutations are T:A>A:T. By
convention, mutations are shown as T>A (for example) rather than A>T, although AA mutations are physical consequences of adducts on adenines that cause A>T
mutations (9, 20, 22–24). In tumors strongly mutagenized by AA, the most prominent peak is at CTG>CAG (CAG>CTG on the complementary strand), indicated in (A),
often with additional prominent peaks at CTA>CAA and ATG>AAG. Small plots at right in (A) to (E) show transcription strand bias. Mut count, mutation count. (F) Mutation
spectra–based principal components analysis of HCCs from Taiwan, China (52), and Japan (53), plus AA-exposed UTUCs (29) and BCs (31) and an AA-exposed cell line (29).
The most distinguishable features are the T>A mutations induced by AA, which are reflected in PC1. PC1 explains 35% of the variance, and PC2 explains 5.5%.
0
T38
T43
T85
T30
T39
T35
T90
T22
T37
T96
T58
T94
T75
T03
T66
T70
T29
T42
T32
T04
T06
T45
T07
T17
T10
T33
T01
T31
T60
T23
T62
T65
T05
T64
T91
T44
T49
T21
T84
T09
T79
T83
T02
T26
T97
T34
T76
T13
T78
T81
T53
T72
T11
T19
T36
T88
T14
T93
T51
T89
T48
T55
T40
T25
T54
T69
T71
T57
T59
T98
T20
T47
T73
T77
T12
T63
T67
T28
T92
T52
T27
T61
T08
T56
T18
T86
T87
T68
T41
T74
T16
T46
T82
T50
T15
T24
T80
T95
Tumor ID
0.0 0.2 0.4 0.6 0.1 0.5 2.0 10.0 50.0 1 5 50 500 0 2 5 10 20
Taiwan
China
Southeast Asia
Vietnam
Korea
Japan
North America
Europe
Mayo Clinic
No information
Fig. 2. Mutational signature exposures in Taiwan HCCs and summary of AA signature mutations. (A) Estimated numbers of mutations due to each mutational
signature in each HCC. AA is COSMIC signature 22. W6 is from (53). COSMIC signatures 4 and 24 reflect known exogenous risk factors for HCC: tobacco smoking and
aflatoxin exposure, respectively. MMR, mismatch repair. (B) Proportions of tumors with the AA signature in various groups of HCCs. “Southeast Asia” indicates Southeast
Asia excluding Vietnam; “Mayo Clinic” denotes a group of HCCs from patients treated at that clinic for whom there was no country information and who we speculate
may have traveled from Asia for treatment; “No information” denotes TCGA HCCs from biobanks for which there is no information on geographic origin. (C) Densities
and counts of AA signature mutations among tumors with the AA signature. Each mutation is associated with a weighted assignment of the probability that it was
caused by the AA signature (see Materials and Methods). The weighted count of AA signature mutations is the sum of these probabilities across all mutations in the
tumors. The geographical regions indicated at the right of (B) also apply to (C).
The AA mutational signature in HCCs from other regions lower in China (median, 0.29 AA signature mutations/Mb) than in Taiwan
Given the high prevalence of the AA signature in Taiwan HCCs, we (median, 2.26 AA signature mutations/Mb).
examined publicly available data comprising 1400 HCCs (Table 1). We detected the AA signature in five of nine HCCs from various
These included data from China, Japan, Korea, and several countries countries in Southeast Asia other than Vietnam (56%; fig. S5, C and
in Southeast Asia (37–39, 46–48, 52, 53), as well as data from North D) (39). Among the HCCs with the AA signature, the median mutation
America and Europe (37, 49) as negative controls with likely rare AA burden was high (2.9 AA signature mutations/Mb). We also detected the
exposure. signature in 5 of 26 HCCs from Vietnam (19%) (37), with a high median
We detected the AA signature in 42 of 89 HCCs (47%) from China mutation burden of 3.4 AA signature mutations/Mb (fig. S5E). We also
(Figs. 2 to 4; Table 1; fig. S5, A and B; and table S11). Among the HCCs detected the AA signature in lower proportions of the HCCs from Korea
from earlier studies (47, 52), the mSigAct signature presence test de- and Japan (Table 1; Figs. 2, B and C, and 3; and fig. S5, F to H).
tected many more affected HCCs than we were able to identify previ- We analyzed TCGA data (37) from areas other than Vietnam in sev-
ously (29). Overall, however, AA signature mutation burdens were eral subgroups (fig. S5I). In the largest subgroup, North America, we
18 October 2017
China 89 1.94 42 0.47 0.29 1.07 5.8 32.6 0.06 0.50 9 2.0 × 10−5
Southeast Asia 9 5.74 5 0.56 2.92 3.07 62.3 43.1 0.08 0.97 2 0.22†
(excluding
Vietnam)
Vietnam 26 3.10 5 0.19 3.42 3.71 125.4 126.8 1.61 2.36 5 7.3 × 10−8
Korea 231 1.78 29 0.13 1.00 1.29 41.4 56.2 1.06 1.18 19 2.1 × 10−30
Japan 477 4.82 13 0.027 0.60 0.94 8.2 13.5 0.04 0.23 3 2.2 × 10−60
SCIENCE TRANSLATIONAL MEDICINE | RESEARCH ARTICLE
North 209 2.36 10 0.048 0.99 2.60 32.9 84.4 0.53 1.51 5 2.6 × 10−40
America
Europe 230 1.67 4 0.017 0.35 9.72 15.2 16.0 0.34 0.35 0 7.3 × 10−49
Mayo Clinic 89 2.94 19 0.21 1.30 2.27 39.2 77.0 0.89 1.46 11 6.0 × 10−15
No 30 2.79 5 0.17 0.46 0.57 13.9 17.1 0.30 0.76 2 2.6 × 10−9
information
Total 1400‡
non-Taiwan
*We ascribe the AA signature to a proportion of each SBS as described in Materials and Methods. Because the AA signature is dominated by A:T>T:A SBS, when the activities of other signatures with these SBS
mutations are low or absent, this approximates the number of A:T>T:A SBS mutations. The weighted counts are the sums of the proportions of SBS mutations ascribed to the AA signature. †P = 7.1 × 10−7,
for all Southeast Asia, including Vietnam. ‡Includes 10 additional TCGA HCCs: 1 Russia, 5 Brazil, 4 South Korea; 1 Brazil HCC has the AA signature.
5 of 12
Downloaded from http://stm.sciencemag.org/ by guest on October 23, 2017
SCIENCE TRANSLATIONAL MEDICINE | RESEARCH ARTICLE
42349
China (HK041, genome)
943 481 1504 5086 1841
0
0.04
China (HK145, genome) 949 1272 962
851 310 243
0.12
Vietnam (CC-A5UD, exome)
47 16 41 146 32 12
0
0.14
Vietnam (ED-A459, exome)
40 10 51 166 40 14
0
0.1
Korea (H050401, exome)
36 7 38 114 28 13
0.12
Korea (H060607, exome)
113
27 9 33 16 6
0
0.08
Japan (HCC16T, exome)
66 35 99 211 66 23
0
0.1
North America (LG-A6GG, exome)
48 20 56 88 46 24
0
0.08
Europe (CHC1756T, exome)
32
28 5 24 24 9
0.12
Mayo Clinic (DD-AACQ, exome)
172
30 22 44 27 16
0
Preceded by 5' A C G T A C G T A C G T A C G T A C G T A C G T
AC A A A A A A A A A A A A A A A A A A A A A A A
Followed by 3' GT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT CGT
Fig. 3. Sample spectra of HCCs with the AA signature. Display conventions are the same as in Fig. 1.
A B
1000
Europe 1000
Number of candidate
neoantigens bound
100 100
Mayo Clinic North America
Unknown
10 10
Brazil
1
AA
Japan Non-AA
Legend 0 1 10 100 1000 0
North America China AA Non-AA
Europe
AA-associated mutations
Northeast Asia Fig. 5. High burdens of AA signature mutations and predicted immuno-
South Korea
Southeast Asia
genicity in Taiwan HCCs. (A) AA signature mutations constitute the majority
Pie charts Southeast Asia of mutations in most Taiwan HCCs affected by the AA mutational signature. (B) Many
AA-negative more in silico predicted candidate neoantigens in AA HCCs than non-AA HCCs;
AA-positive Taiwan
P value by Wilcoxon rank sum test.
antigen (HLA) types. HCCs with the AA signature had many more To summarize the findings of this study, mutational signature anal-
predicted neoantigens (median, 146.5) than the remaining Taiwan ysis implicated AA exposure in 78% of HCCs from Taiwan. The AA
HCCs (median, 60; P < 2 × 10−8 by Wilcoxon rank sum test; Fig. 5). signature was much more prevalent, and the number and proportion
of mutations were notably higher in Taiwan than in most other regions.
At the same time, AA exposure was found in cohorts from all Asian
DISCUSSION countries examined and in 22% of Asian patients treated at the Mayo
Some AA-containing herbal remedies have been officially prohibited in Clinic. Across Taiwan HCCs, 299 of 505 nonsilent mutations in known
Taiwan since 2003, and we looked for evidence of whether this ban re- driver genes were ascribed to the AA signature. Among the 76 AA-
duced exposure. We detected no significant difference in the prevalence affected Taiwan HCCs, 57 had ≥1 nonsilent AA mutation in a known
of the AA signature or in the numbers of AA signature mutations in driver, and among the 133 AA-affected HCCs from elsewhere, 56 had
HCCs diagnosed before and after 2003. There are a number of possible, ≥1 nonsilent AA mutation in a known driver gene, suggesting an active
nonexclusive explanations. One possibility is that the decline in inci- role for AA in the origins of these HCCs.
dence of AA-associated HCCs may simply be lagging behind reduced The findings here indicate that exposure to aristolochic acids and
AA exposure. There is precedent for this in tobacco-associated lung their derivatives is geographically widespread, implying substantial op-
cancer. In the United States, male death rates roughly doubled in the portunities for primary and secondary prevention (Fig. 4). Medicinal
25 years after the 1964 Surgeon General’s Report before beginning to use of AA-containing plants is only lightly regulated in many jurisdic-
decline in the 1990s, presumably as a result of tobacco suppression ef- tions. The plants are not banned outright in China (67), and even in
(103-6534C) and National Taiwan University Institutional Review invariant mutation types in trinucleotide context, namely, ACA>AAA,
Boards and Human Research Ethics Committees. Table S1 provides clin- ACA>AGA, ACA>ATA, CCA>CAA, …, TTT>TAT, TTT>TCT, and
icopathological data and information on sequencing. TTT>TGT (see also the labels at the bottom of Fig. 1E). Let nS be the
number of mutational signatures, and lete1 …enS be the exposures of the
Whole-exome sequencing and mutation identification tumor to each of the signatures. Let p(tj, Si) be the proportion of muta-
tion type tj in signature Si, with 1 ¼ ∑j¼1 pðtj ;Si Þ. Then, in a given
96
Samples were captured with the Agilent SureSelect V5 exome panels.
Paired 101–base pair reads were generated on HiSeq 2500 sequencers. tumor, we define the partial contribution of Si to each instance of tj as
BWA-MEM aligned reads to the human reference genome (hg19) (70),
SAMtools removed polymerase chain reaction duplicates (71), and n
pðtj ;Si Þ⋅ei =∑k¼1
S
pðtj ;Sk Þ⋅ek
Qualimap 2 computed quality control metrics (72). Candidate somatic
mutations were initially identified by three callers: GATK (73), Strelka
(74), and MuTect (75). SBS called by ≥2 callers and small indels called in which the denominator ensures that the partial credits sum to 1.
by both GATK and Strelka were curated for downstream analysis. Ex-
amination of ≥1% of SBS calls and ≥1% indel calls from each tumor- AA signature mutations in driver genes
normal pair (with ≥1 mutation from each tumor-normal pair) in IGV We used MutSigCV (42) and 20/20+ (43) to identify candidate drivers
indicated an FDR of 6/312 (1.9%) of SBS calls and 3/93 (3.2%) of indel in the Taiwan AA HCCs (tables S6 to S8). The MutSigCV preprocessor
calls (table S3). Indels were rare, and their length distribution was un- was used to generate the MAF file, and MutSigCV was run with default
Table S9. AA signature mutations and effects on driver genes in 98 Taiwan HCCs. 15. M.-N. Lai, S.-M. Wang, P.-C. Chen, Y.-Y. Chen, J.-D. Wang, Population-based case-control
Table S10. Comparison of LA-NMF–extracted AA signatures with COSMIC 22. study of Chinese herbal products containing aristolochic acid and urinary tract cancer
Table S11. List of AA signature–positive HCCs from publicly available data. risk. J. Natl. Cancer Inst. 102, 179–186 (2010).
Table S12. Known oncogene and tumor suppressor drivers from COSMIC Cancer Gene Census. 16. M. J. Martena, J. C. A. van der Wielen, L. F. J. van de Laak, E. J. M. Konings,
Table S13. Nonsilent mutations in known cancer driver genes plus genes identified by H. N. de Groot, I. M. C. M. Rietjens, Enforcement of the ban on aristolochic acids in
MutSigCV or 20/20+. Chinese traditional herbal preparations on the Dutch market. Anal. Bioanal. Chem.
Table S14. Subclonality analysis of AA mutations in published HCC multiregion sequencing 389, 263–275 (2007).
studies. 17. International Agency for Research on Cancer, Some traditional herbal medicines, some
Table S15. Likely AA-containing plants for sale on the internet. mycotoxins, naphthalene and styrene, in IARC Monographs On The Evaluation Of
Table S16. Selecting the negative binomial dispersion parameter for mSigAct. Carcinogenic Risks To Humans (IARC Press, 2002), vol. 82.
Table S17. True- and false-positive rates for detection of the AA signature by mSigAct and 18. M. Heinrich, J. Chan, S. Wanke, C. Neinhuis, M. S. J. Simmonds, Local uses of Aristolochia
LA-NMF. species and content of nephrotoxic aristolochic acid 1 and 2—A global assessment
Table S18. Comparison of detection of the AA signature by mSigAct and LA-NMF on 1400 based on bibliographic sources. J. Ethnopharmacol. 125, 108–144 (2009).
publicly available HCC spectra. 19. Final Report on Carcinogens Background Document for Aristolochic Acids (U.S. Department
Code S1. Code for analyses presented in this paper, including mSigAct.v0.8.R and mSigTools. of Health and Human Services, Public Health Services, Public Health Services, 2008);
v0.7.R. https://ntp.niehs.nih.gov/ntp/roc/twelfth/2010/finalbds/aristolochic_acids_final_508.pdf.
Code S2. Analysis and tests of HCCs with mSigAct and the NMF procedure from (3, 4). 20. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, Some
References (82–90) traditional herbal medicines, some mycotoxins, naphthalene and styrene, in IARC
Monographs on the Evaluation of Carcinogenic Risks to Humans (IARC Press, 2002).
21. M. Stiborová, E. Frei, V. M. Arlt, H. H. Schmeiser, Metabolic activation of carcinogenic
aristolochic acid, a risk factor for Balkan endemic nephropathy. Mutat. Res. 658, 55–67
REFERENCES AND NOTES
D. Lechner, M. Foglio, I. G. Gut, K. Skryabin, E. Prokhortchouk, A. Cambon-Thomsen, 48. S. M. Ahn, S. J. Jang, J. H. Shim, D. Kim, S. M. Hong, C. O. Sung, D. Baek, F. Haq, A. A. Ansari,
J. Rung, G. Bourque, P. Brennan, J. Tost, R. E. Banks, A. Brazma, G. M. Lathrop, Variation in S. Y. Lee, S.-M. Chun, S. Choi, H.-J. Choi, J. Kim, S. Kim, S. Hwang, Y.-J. Lee, J.-e. Lee,
genomic landscape of clear cell renal cell carcinoma across Europe. Nat. Commun. 5 W.-r. Jung, H. Y. Jang, E. Yang, W.-K. Sung, N. P. Lee, M. Mao, C. Lee, J. Zucman-Rossi, E. Yu,
(2014). H. C. Lee, G. Kong, Genomic portrait of resectable hepatocellular carcinomas: Implications
34. M. L. Hoang, C.-H. Chen, P.-C. Chen, N. J. Roberts, K. G. Dickman, B. H. Yun, R. J. Turesky, of RB1 and FGF19 aberrations for patient stratification. Hepatology 60, 1972–1982 (2014).
Y.-S. Pu, B. Vogelstein, N. Papadopoulos, A. P. Grollman, K. W. Kinzler, T. A. Rosenquist, 49. K. Schulze, S. Imbeaud, E. Letouzé, L. B. Alexandrov, J. Calderaro, S. Rebouissou,
Aristolochic acid in the etiology of renal cell carcinoma. Cancer Epidemiol. Biomarkers G. Couchy, C. Meiller, J. Shinde, F. Soysouvanh, A.-L. Calatayud, R. Pinyol, L. Pelletier,
Prev. 25, 1600–1608 (2016). C. Balabaud, A. Laurent, J.-F. Blanc, V. Mazzaferro, F. Calvo, A. Villanueva, J.-C. Nault,
35. S. Zou, J. Li, H. Zhou, C. Frech, X. Jiang, J. S. Chu, X. Zhao, Y. Li, Q. Li, H. Wang, Mutational P. Bioulac-Sage, M. R. Stratton, J. M. Llovet, J. Zucman-Rossi, Exome sequencing of
landscape of intrahepatic cholangiocarcinoma. Nat. Commun. 5, 5696 (2014). hepatocellular carcinomas identifies new mutational signatures and potential therapeutic
36. A. Jusakul, I. Cutcutache, C. H. Yong, J. Q. Lim, M. N. Huang, N. Padmanabhan, V. Nellore, targets. Nat. Genet. 47, 505–511 (2015).
S. Kongpetch, A. W. T. Ng, L. M. Ng, S. P. Choo, S. S. Myint, R. Thanan, S. Nagarajan, 50. A. Fischer, C. J. R. Illingworth, P. J. Campbell, V. Mustonen, EMu: Probabilistic inference
W. K. Lim, C. C. Y. Ng, A. Boot, M. Liu, C. K. Ong, V. Rajasegaran, S. Lie, A. S. T. Lim, T. H. Lim, of mutational processes and their localization in the cancer genome. Genome Biol.
J. Tan, J. L. Loh, J. R. McPherson, N. Khuntikeo, V. Bhudhisawasdi, P. Yongvanit, 14, R39 (2013).
S. Wongkham, Y. Totoki, H. Nakamura, Y. Arai, S. Yamasaki, P. K.-H. Chow, A. Y. F. Chung, 51. R. Rosenthal, N. McGranahan, J. Herrero, B. S. Taylor, C. Swanton, DeconstructSigs:
L. L. P. J. Ooi, K. H. Lim, S. Dima, D. G. Duda, I. Popescu, P. Broet, S.-Y. Hsieh, M.-C. Yu, Delineating mutational processes in single tumors distinguishes DNA repair deficiencies
A. Scarpa, J. Lai, D.-X. Luo, A. L. Carvalho, A. L. Vettore, H. Rhee, Y. N. Park, L. B. Alexandrov, and patterns of carcinoma evolution. Genome Biol. 17, 31 (2016).
R. Gordán, S. G. Rozen, T. Shibata, C. Pairojkul, B. T. Teh, P. Tan, Whole-genome and 52. W.-K. Sung, H. Zheng, S. Li, R. Chen, X. Liu, Y. Li, N. P. Lee, W. H. Lee, P. N. Ariyaratne,
epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. C. Tennakoon, F. H. Mulawadi, K. F. Wong, A. M. Liu, R. T. Poon, S. T. Fan, K. L. Chan,
Cancer Discov. (2017). Z. Gong, Y. Hu, Z. Lin, G. Wang, Q. Zhang, T. D. Barber, W.-C. Chou, A. Aggarwal, K. Hao,
37. The Cancer Genome Atlas Research Network, Comprehensive and integrative genomic W. Zhou, C. Zhang, J. Hardwick, C. Buser, J. Xu, Z. Kan, H. Dai, M. Mao, C. Reinhard,
66. W. Chan, H. Yue, W. T. Poon, Y.-W. Chan, O. J. Schmitz, D. W. J. Kwong, R. N. S. Wong, during indolent chronic lymphocytic leukaemia evolution. Nat. Commun. 6, 8866
Z. Cai, Quantification of aristolochic acid-derived DNA adducts in rat kidney (2015).
and liver by using liquid chromatography–electrospray ionization mass spectrometry. 84. J. S. Gehring, B. Fischer, M. Lawrence, W. Huber, SomaticSignatures: Inferring mutational
Mutat. Res. 646, 17–24 (2008). signatures from single-nucleotide variants. Bioinformatics 31, 3673–3675 (2015).
67. China Food and Drug Administration, Notice concerning strengthened supervision of 85. M. Ardin, V. Cahais, X. Castells, L. Bouaoun, G. Byrnes, Z. Herceg, J. Zavadil, M. Olivier,
guang fang ji and six other herbs and their pharmaceutical preparations (2004); MutSpec: A Galaxy toolbox for streamlined analyses of somatic mutation spectra in
www.sda.gov.cn/WS01/CL0844/10242.html. human and mouse cancer genomes. BMC Bioinformatics 17, 170 (2016).
68. United States Congress, Dietary Supplement Health and Education Act of 1994 (1994); 86. R. A. Rosales, R. D. Drummond, R. Valieris, E. Dias-Neto, I. T. da Silva, signeR: An
www.gpo.gov/fdsys/pkg/STATUTE-108/pdf/STATUTE-108-Pg4325.pdf. empirical Bayesian approach to mutational signature discovery. Bioinformatics 33,
69. C. L. Wah, S. C. Hock, T. K. Yun, Current scientific status and regulatory control of 8–16 (2016).
traditional/herbal medicinal products: Globalization challenges. Pharm. Eng. 32, 1–15 87. A. Ozerov, C. Févotte, R. Blouet, J.-L. Durrieu, Multichannel nonnegative tensor
(2012). factorization with structured constraints for user-guided audio source separation, 2011
70. H. Li, R. Durbin, Fast and accurate short read alignment with Burrows-Wheeler transform. IEEE International Conference on Acoustics Speech and Signal Processing (ICASSP), Prague,
Bioinformatics 25, 1754–1760 (2009). Czech Republic, 22 to 27 May 2011 (IEEE, 2011).
71. H. Li, B. Handsaker, A. Wysoker, T. Fennell, J. Ruan, N. Homer, G. Marth, G. Abecasis, 88. M. J. Powell, Advances in Optimization and Numerical Analysis (Springer, 1994), pp. 51–67.
R. Durbin, The sequence alignment/map format and SAMtools. Bioinformatics 25, 89. A. Pascual-Montano, J. M. Carazo, K. Kochi, D. Lehmann, R. D. Pascual-Marqui, Nonsmooth
2078–2079 (2009). nonnegative matrix factorization (nsNMF). IEEE Trans. Pattern Anal. Mach. Intell. 28,
72. K. Okonechnikov, A. Conesa, F. García-Alcalde, Qualimap 2: Advanced multi-sample 403–415 (2006).
quality control for high-throughput sequencing data. Bioinformatics 32, 292–294 (2016). 90. C. H. Mermel, S. E. Schumacher, B. Hill, M. L. Meyerson, R. Beroukhim, G. Getz, GISTIC2.
73. A. McKenna, M. Hanna, E. Banks, A. Sivachenko, K. Cibulskis, A. Kernytsky, K. Garimella, 0 facilitates sensitive and confident localization of the targets of focal somatic
D. Altshuler, S. Gabriel, M. Daly, M. A. DePristo, The Genome Analysis Toolkit: A copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).
SUPPLEMENTARY http://stm.sciencemag.org/content/suppl/2017/10/16/9.412.eaan6446.DC1
MATERIALS
RELATED http://stm.sciencemag.org/content/scitransmed/5/197/197ra101.full
CONTENT
http://stm.sciencemag.org/content/scitransmed/5/197/197pc5.abstract
http://stm.sciencemag.org/content/scitransmed/5/197/197ra102.full
http://stm.sciencemag.org/content/scitransmed/5/197/197fs31.full
REFERENCES This article cites 76 articles, 10 of which you can access for free
http://stm.sciencemag.org/content/9/412/eaan6446#BIBL
PERMISSIONS http://www.sciencemag.org/help/reprints-and-permissions
Science Translational Medicine (ISSN 1946-6242) is published by the American Association for the Advancement of
Science, 1200 New York Avenue NW, Washington, DC 20005. 2017 © The Authors, some rights reserved; exclusive
licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. The
title Science Translational Medicine is a registered trademark of AAAS.